• Harro Höfliger announces availability of commercial scale dry-filling technology for MDIs

  Harro Höfliger says that dry-filling technology for metered dose inhaler production, which has previously been available only at laboratory scale, is now available for commercial scale production lines. Dry filling, which Harro has developed in… [Read more . . .]

• Macquarie University research project on formulation of inhaled dry powder biologics will involve Aptar Pharma’s Orbital DPI

  Aptar Pharma has announced that its Orbital high-payload dry powder inhaler will be key to a Macquarie University research project titled “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” which is funded by a… [Read more . . .]

• AstraZeneca’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI approved by the EU for the treatment of asthma

  AstraZeneca announced that the European Commission has approved the company’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older whose asthma is not adequately… [Read more . . .]

• CF Pharmtech initiates Phase 1 trial of ICF004 antifibrotic DPI

  Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… [Read more . . .]

• Polyrizon initiates trial of Nasarix (PL-14) intranasal allergen blocker for seasonal allergic rhinitis

  Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… [Read more . . .]

• Bespak and Upperton team up to offer nasal drug development and manufacturing services

• FDA accepts Insmed’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for MAC lung disease

• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

• FDA clears IND for Phase 1b trial of SMSbiotech’s inhaled stem cell therapy in patients with COPD

• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

More news . . .